Skip to main content

Table 1 Background characteristics by study group*

From: Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan

 

Misoprostol

(800mcg SL)

(n = 40)

Placebo

(n = 39)

Age, mean ± SD

24.7 ± 4.8

26.0 ± 5.5

Parity, mean ± SD

3.1 ± 1.9

2.9 ± 1.8

Woman categorized as literate

8 (20.0)

8 (20.5)

Iron folate tablets taken during pregnancy

38 (95.0)

38 (100) a

Duration during which iron folate tablets were taken (months), mean + SD

1.9 ± 1.5

2.4 ± 2.3 a

Pre-delivery Hb (g/dL) b

 mean ± SD

12.4 ± 1.4

12.1 ± 1.8

 (range)

(9.0–15.9)

(7.7–15.8)

  1. Abbreviations: Hb hemoglobin, SL sublingual
  2. * Data presented as n (%) unless otherwise stated
  3. an = 38; data on iron folate missing for one case in the placebo arm
  4. b In six cases (misoprostol, n = 1; placebo, n = 5) pre-delivery Hb was not measured due to enrollment in the study at the time of the delivery